SW
TCRR

SVB Wealth’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

SVB Wealth’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-42,084
Closed -$358K – 976
2021
Q3 		$358K Sell
42,084
-42,083
-50% -$595K ﹤0.01% 710
2021
Q2 		$1.38M Buy
84,167
+11,633
+16% +$235K 0.02% 322
2021
Q1 		$1.6M Hold
72,534
– – 0.02% 271
2020
Q4 		$2.24M Sell
72,534
-9,375
-11% -$237K 0.03% 218
2020
Q3 		$1.66M Hold
81,909
– – 0.03% 233
2020
Q2 		$1.26M Buy
81,909
+32,934
+67% +$380K 0.02% 244
2020
Q1 		$379K Hold
48,975
– – 0.01% 354
2019
Q4 		$699K Buy
+48,975
New +$757K 0.01% 360

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SVB Wealth's TCRR Position: Q4 2021 in Review

SVB Wealth sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 42,084 shares — an estimated $358K sold.

SVB Wealth first reported a position in TCRR in Q4 2019 and held it in 8 quarters. The position peaked at $2.24M in Q4 2020. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

  • SVB Wealth reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • SVB Wealth sold 42,084 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $358K.
  • SVB Wealth first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2019 and held it in 8 quarters.
  • SVB Wealth's TCR2 Therapeutics Inc. Common Stock position peaked at $2.24M in Q4 2020.
  • 122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on SVB Wealth's 13F filing for Q4 2021, filed 15 Feb 2022.